Tri-Heal (TB-500 25mg + BPC-157 10mg + KPV 10mg)
A research-focused multi-peptide blend combining TB-500, BPC-157, and KPV targeting soft-tissue repair, cellular recovery, and inflammation.
Mechanism
The blend functions via TB-500 actin-sequestering cellular migration, BPC-157 angiogenic tissue remodeling, and KPV anti-inflammatory modulation of cellular signaling cascades.
Dosing
Standard investigational baseline administration utilizes 10 units (0.10 mL) once daily from the 15 mg/mL solution, delivering 1.5 mg total peptide (0.833 mg TB-500, 0.333 mg BPC-157, and 0.333 mg KPV).
Reconstitution
Reconstituting the 45 mg composite vial with 3.0 mL of bacteriostatic water yields an aggregate concentration of approximately 15 mg/mL.
Storage
Store unmixed lyophilized vials at -20 °C in dark conditions, and keep reconstituted solutions refrigerated at 2 to 8 °C for up to 28 days without freezing.
Mix & measure Tri-Heal (TB-500 25mg + BPC-157 10mg + KPV 10mg)
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Tri-Heal (TB-500 25mg + BPC-157 10mg + KPV 10mg)
Vial strength → BAC water → target dose
Total doses in vial: 30.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 (Standard) | 0.833 mg TB-500 + 0.333 mg BPC-157 + 0.333 mg KPV (1× daily) | 10 units (0.10 mL) |
| Weeks 5–8 (Standard Optional) | 0.833 mg TB-500 + 0.333 mg BPC-157 + 0.333 mg KPV (1× daily) | 10 units (0.10 mL) |
| Weeks 1–4 (Advanced) | 1.667 mg TB-500 + 0.667 mg BPC-157 + 0.667 mg KPV (1× daily) | 20 units (0.20 mL) |
| Weeks 5–6 (Advanced) | 1.667 mg TB-500 + 0.667 mg BPC-157 + 0.667 mg KPV (1× daily) | 20 units (0.20 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release the diluent slowly along the inner glass wall of the vial to minimize agitation and foaming.
- 3
Gently roll or swirl the vial until the lyophilized cake is fully dissolved, avoiding vigorous shaking.
- 4
Document the preparation date on the vial label and transfer immediately to cold storage at 2–8 °C.
Supplies Needed
Peptide Vial
Tri-Heal lyophilized blend vial containing 45 mg total peptide (25 mg TB-500, 10 mg BPC-157, 10 mg KPV).
Insulin Syringes (U-100)
Sterile 1 mL / 100-unit syringes used to precisely draw and administer micro-volume subcutaneous doses.
Bacteriostatic Water
Preserved diluent containing benzyl alcohol used to dissolve 45 mg of lyophilized powder at a 3.0 mL volume.
Alcohol Swabs
Antiseptic wipes to disinfect rubber vial septums and prepare experimental injection sites prior to administration.
Why researchers study it
Preclinical soft-tissue remodeling and cellular migration
Experimental tendon, ligament, and skeletal muscle regeneration
Modulation of systemic and localized inflammatory pathways
Gastrointestinal and mucosal epithelial barrier integrity
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Tri-Heal is an experimental composite peptide formulation bringing together TB-500 (25 mg), BPC-157 (10 mg), and KPV (10 mg) into a single 45 mg container. Fixed at a 5:2:2 proportion, this blend is structured to assess multi-target regenerative pathways concurrently in preclinical models, evaluating both structural cellular remodeling and anti-inflammatory mechanisms. TB-500 acts as an actin-binding fragment related to Thymosin Beta-4, while BPC-157 functions as an angiogenic pentadecapeptide and KPV supplies a tripeptide derived from alpha-MSH. Because all three molecules are co-formulated within one container, experimental dosing scales each component proportionally, preventing individual dose titration. This blend is unstudied in formal human clinical trials and remains classified strictly as an unapproved research reagent. Investigators should recognize that all established data originates from separated preclinical animal trials or in vitro bioassays.
References
- 1.Philp et al., FASEB Journal, 2003 — Biological activities of thymosin beta-4 mapped to active peptide sequences
- 2.Esposito et al., Journal of Chromatography A, 2012 — Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment
- 3.Malinda et al., Journal of Investigative Dermatology, 1999 — Thymosin beta-4 accelerates wound healing in a preclinical model
- 4.Sosne et al., FASEB Journal, 2002 — Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration
- 5.Philp et al., Journal of Investigative Dermatology, 2004 — Thymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allMelanotan II + PT-141 10+10 mg
Melanotan II and PT-141 stack pairing melanocortin receptor agonists for experimental pigmentation and central sexual arousal pathways.
View ProtocolAOD-9604 + CJC-1295 + Ipamorelin 12mg Blend
A 12 mg multi-pathway research blend uniting lipolytic fragment AOD-9604 with CJC-1295 and Ipamorelin for amplified GH axis signaling.
View ProtocolCJC-1295 DAC + Ipamorelin 5+5 mg
Dual GH-secretagogue stack combining extended-release CJC-1295 DAC with pulsatile Ipamorelin for synergistic endocrine axis research.
View Protocol